Burcin Erkal Çam

Dr. Burcin Erkal Çam

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2018 in American Journal of Men's Health
Verified
Journal Article
Open access
PDF file
BÇBurcin Erkal Çam
Burcin Erkal Çam
AKAysel Kalayci
Aysel Kalayci
SPSukru Palanduz
Sukru Palanduz
SDSelcuk Dasdemir
Selcuk Dasdemir
MSMehmet Seven
Mehmet Seven
Klinefelter syndrome (KS) is a common sex chromosome-related abnormality seen among men. KS negatively affects spermatogenesis and testosterone production. It increases the risk of thrombosis but its molecular mechanism has not been well described yet. Elevated PAI-1 is a risk factor for thrombosis. The rs1799889 polymorphism located in the promoter region of the PAI-1 gene was detected in patients with deep venous thrombosis. In this study, the PAI-1 gene variant and its plasma levels in KS patients were examined. Forty-one KS patients (47, XXY) and 50 age-matched healthy controls participated. DNA was isolated from peripheral blood and a real-time PCR method was used to detect known SNPs in the PAI-1 gene. In addition, PAI-1 plasma levels were measured by using ELISA method. There was no significant difference between PAI-1 gene polymorphisms of KS patients and controls (p > .05). The significant difference was observed in PAI-1 plasma levels between two groups (high PAI-1 plasma level in KS patients compared to controls). The patients’ group mean was 55.13 and control group mean in PAI-1 level was 29.89 ng/ml (p = .020). Clinical features related to thromboembolism especially varicose veins were detected in KS patients frequently (p = .04). These results suggest that thromboembolism related to clinical features is seen more frequently in cases with KS, but it may not be dependent only on the PAI-1 gene polymorphism structure.

23 December 2022 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
TKTuğba Kul Köprülü
Tuğba Kul Köprülü
BÇBurcin Erkal Çam
Burcin Erkal Çam
AKAltan Kara
Altan Kara
ŞTŞaban Tekin
Şaban Tekin

22 October 2022 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
BÇBurcin Erkal Çam
Burcin Erkal Çam
BABetül Akçeşme
Betül Akçeşme
AÇArzu Çoban
Arzu Çoban
ŞKŞenay Vural Korkut
Şenay Vural Korkut


21 January 2025 in Medical Oncology
Verified
Journal Article
Open access
PDF file
TKTuğba Kul Köprülü
Tuğba Kul Köprülü
BGBahar Gezer
Bahar Gezer
BÇBurcin Erkal Çam
Burcin Erkal Çam
Lung and colon cancer are among the most commonly diagnosed and fatal cancer types in the world. Due to their metastatic properties, they complicate the treatment process and pose a great threat to human health. These aggressive types of cancer are resistant to chemotherapy drugs. Therefore, it is extremely important to investigate the therapeutic effects of natural compounds. In our previous study, effective doses of Royal Jelly (RJ) (100 mg/mL) and Aloe vera (AVE) (20 µg/mL) were determined and tested separately and in combination on lung and colorectal cancer cells. Glycolytic capacities were determined using the Seahorse XFe24 Analyzer, total transcriptome profiles were sequenced using NovaSeq 6000, and BAX and BCL-2 gene levels were determined using RT-qPCR. It was seen that RJ and RJ + AVE affected glycolytic capacity and more genes in lung cancer cells. In HT29, AVE alone was seen to reduce glycolytic capacity and RJ + AVE combination was seen to reduce the expression level of genes related to cell proliferation and cycle. After RJ + AVE treatments, the apoptotic process which is triggered via MAPK pathway was found in lung cancer. Moreover, BAX levels increased and BCL-2 levels decreased both lung and colorectal cancer cells. It was observed that the combination of RJ and AVE affected the glycolysis process, cell cycle, proliferation and apoptosis on lung and colorectal cancer. In particular, the combination of RJ + AVE was found to be more effective on lung cancer.

27 June 2025 in Breast Cancer
Verified
Journal Article
Open access
PDF file
TKTuğba Kul Köprülü
Tuğba Kul Köprülü
SASerhat Aras
Serhat Aras
BÇBurcin Erkal Çam
Burcin Erkal Çam
AKAltan Kara
Altan Kara
The objective of this study was to investigate the acute radiobiological mechanisms underlying Flattening Filter (FF) and Flattening Filter Free (FFF) radiotherapy-induced inhibition of breast cancer (BCa) by detecting changes in gene expression levels. The study involved thirty-six adult nude mice models that were randomly divided into five groups: control (G1), breast cancer (BCa) (G2), FF-400 (G3), FFF-1120 (G4), and FFF-1820 (G5). The control group had no radiation or treatment, while the BCa group had a cancer model but no radiation. The BCa models were subjected to a single dose of 20 Gy of radiotherapy at varying dose rates: 400, 1120, and 1820 MU/min (G3, G4, and G5, respectively). Twenty days after implantation of the MCF-7 cancer cell line, nude mice were irradiated and sacrificed 48 h later for genetic analysis. A transcriptome library was created by extracting RNA from tissue samples. In the differentially expressed genes (DEG) analysis, a total of 1565 genes were found to be significantly altered in the G2 vs. G1 groups. When radiotherapy groups (G3, G4, and G5) were analyzed, 334 DEGs (231 down, 103 up) were identified in G3 vs G2 data, 167 DEGs (103 down, 64 up) in G4 vs G2 data, and 187 DEGs (116 down, 71 up) in G5 vs G2 data. Gene Ontology molecular function analysis revealed significant differences between groups G3 and G2, with an emphasis on protein binding, glutamate receptor activity, and interleukin-8 receptor activation. Similar features were observed when comparing groups G5 and G2. The analysis showed significant differences in the expression of the key ERAD pathway genes Ufd1 and Cav1 between the BCa and radiotherapy groups. It was concluded that the FFF beam significantly alters the processes underlying the ERAD pathway and glutamate receptor activation compared to the FF beam.